Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Fig. 3

Progression-free survival (PFS) (A) and overall survival (OS) (B) of patients with EGFR-mutant advanced NSCLC without concomitant mutations (EGFR_only) and those with concomitant gene mutations in either tumor suppressor genes (EGFR_Suppressor) or oncogenic driver genes (EGFR_multiDriver) treated with either EGFR-TKI with bevacizumab (A+T) or EGFR-TKI monotherapy (T-single)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us